Eliaz Therapeutics is developing a novel treatment using targeted therapeutic apheresis to remove Galetin-3 from the body
Eliaz Therapeutics has raised $642K in total funding. The most recent round was Equity Crowdfunding. The last funding was announced in May 2026.
Eliaz Therapeutics's investors include National Institutes of Health.
Eliaz Therapeutics is headquartered in Santa Rosa, United States.
Eliaz Therapeutics is developing a novel treatment using targeted therapeutic apheresis to remove Galetin-3 from the body
Eliaz Therapeutics is at the Equity Crowdfunding stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Eliaz Therapeutics — Funding & Investors." VCBacked, May 1, 2026, https://www.vcbacked.co/company/eliaz-therapeutics. Accessed July 18, 2026.
VCBacked. (2026). Eliaz Therapeutics — Funding & Investors. Retrieved July 18, 2026, from https://www.vcbacked.co/company/eliaz-therapeutics
{{cite web |title=Eliaz Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/eliaz-therapeutics |website=VCBacked |access-date=July 18, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated